Clinical Trials Directory

Trials / Unknown

UnknownNCT04359303

Indirect Endovenous Systemic Ozone for New Coronavirus Disease (COVID19) in Non-intubated Patients

Randomized Clinical Trial to Evaluate Efficacy and Safety of Systemic Indirect Endovenous Ozone Therapy (SIEVOT) as Adjuvant Treatment in COVID19 Non-intubated Patients

Status
Unknown
Phase
Phase 3
Study type
Interventional
Enrollment
50 (estimated)
Sponsor
Javier Hidalgo Tallón · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Systemic medical ozone has proved to help in several viral diseases, chronic obstructive pulmonary disease and chronic inflammation process. The investigators are sure that its application to COVID-19 patients, as an adjuvant therapy, will improve the health status of these individuals.

Detailed description

Due to the extreme world situation caused by COVID19 pandemic, the investigators consider unethical not to try any treatment option with a justified rationale. The investigators have explained that medical ozone therapy has a clear scientific basement thanks to all preclinical and clinical investigation already published. It can be classified as chemical stressor that produces a modulation in the redox balance and immunity. Moreover, it is easy and safe to administer with insignificant side effects. The efficacy in viral diseases has been proved in publications together the modulation of interleukin 6 and other proinflammatory cytokines that could potentially help in COVID19 patients. The improve of exchange of gases and microcirculation will surely contribute to enhance this patients' health status. As explained above, the investigators propose to carry out a randomized control trial to evaluate the safety and efficacy of systemic ozone (indirect endovenous) in these patients.

Conditions

Interventions

TypeNameDescription
OTHERSystemic indirect endovenous ozone therapy200 mL at 40 mcg/mL of medical ozone / oxygen in 200 mL of patients blood mixed in an homologated device for the procedure.

Timeline

Start date
2020-07-01
Primary completion
2020-11-01
Completion
2020-12-01
First posted
2020-04-24
Last updated
2020-06-23

Locations

1 site across 1 country: Spain

Source: ClinicalTrials.gov record NCT04359303. Inclusion in this directory is not an endorsement.